Search

A patent application by inventors from the University of Massachusetts focuses on energy absorbing structures derived from bovid horncore bone morphology. These structures are intended for use in various applications such as helmet liners, protective gear, and packaging material, providing a lightweight and cost-effective alternative to traditional materials. The patent application outlines methods for creating these energy absorbing structures, including forming irregular lattice patterns based on bovid skull horncore morphology and utilizing additive manufacturing techniques. [Extracted from the article]

A patent has been issued for compositions and methods for treating expanded repeat-associated disorders, particularly focusing on neurological diseases such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The patent highlights the discovery of translation start sites for toxic dipeptide repeat (DPR) protein synthesis in C9ORF72 mRNAs, offering potential therapeutic avenues for these diseases. The patent emphasizes the use of translation modulating agents, such as antisense oligonucleotides (ASOs), to disrupt translation initiation and modulate mRNA expression. This research is significant for understanding and potentially treating ALS and FTD associated with repeat expansion regions. [Extracted from the article]

Researchers from the University of Massachusetts have submitted a patent application for "Modified Aav Constructs And Uses Thereof" to the USPTO. The application focuses on enhancing the replication and packaging efficiency of rAAV vectors containing hairpin-forming RNA cassettes for gene silencing in vivo. The invention involves utilizing DNA fragments encoding RNA hairpin structures to generate self-complementary vector genomes, providing a valuable tool for gene function studies and gene therapy applications. The patent application outlines various embodiments and methods for efficient, safe, and sustained in vivo gene silencing using rAAV vectors and artificial miRNA constructs. [Extracted from the article]

A patent has been issued for the DNase H activity of Neisseria meningitidis Cas9 by the University of Massachusetts. This invention relates to gene editing, specifically focusing on a Neisseria meningitidis Cas9 enzyme that efficiently cleaves single-stranded DNA in an RNA-guided, tracrRNA-independent manner. The patent outlines methods for reducing symptoms of virus infections by administering a pharmaceutical composition containing the NmeCas9 enzyme and a guide RNA sequence. The invention targets single-stranded viral DNA sequences, including those of hepatitis B virus, retroviruses, lentivirus, and human immunodeficiency virus. [Extracted from the article]

A patent has been issued for compositions and methods for differential Cas9 gene labeling and editing. The patent describes a system that can be used to differentiate stem cells and identify genes related to cell differentiation. It also discusses the organization of a cell nucleus and methods for labeling specific genomic loci in live cells. The invention provides methods for modifying the transcriptional regulation of stem or progenitor cells and for multiplex gene editing and labeling. The patent describes methods for gene editing and labeling using Cas9 proteins, which involve introducing specific genomic loci and Cas9 proteins into live cells. The edited genomic loci can be detected using fluorescence microscopy or fluorescence activated cell sorting. The patent was filed by Metewo Selase Kosi Enuameh from the University of Massachusetts. [Extracted from the article]

A patent has been issued to the University of Massachusetts for a method of therapeutic alteration of transplantable tissues using RNA interference molecules. The invention aims to minimize organ rejection, transmission of viral infections during transplantation, and apoptosis in transplanted tissues. The RNA interference molecules can be delivered to transplantable tissues through various methods, such as perfusion or injection. The patent also includes methods for treating organs at risk of apoptosis-induced ischemic injury. The invention has potential applications in treating various organs, including the kidney, liver, pancreas, heart, and lung. [Extracted from the article]

A patent has been issued to the University of Massachusetts for modified adeno-associated virus (AAV) constructs and their uses in gene therapy. The patent describes methods and compositions that increase the replication and packaging efficiency of AAV vectors containing hairpin-forming RNA cassettes, which are valuable tools for gene function studies and gene therapy applications. The invention is based on the discovery that DNA fragments encoding RNA hairpin structures can serve a function similar to a mutant inverted terminal repeat (ITR) during viral genome replication, generating self-complementary vector genomes. This technology allows for efficient, safe, and sustained in vivo gene silencing. [Extracted from the article]

A patent has been issued for oligonucleotides that can modulate gene expression in specific tissues, particularly in the central nervous system (CNS). The patent focuses on the potential use of these oligonucleotides in the treatment of neurodegenerative diseases such as Alzheimer's disease and Amyotrophic Lateral Sclerosis (ALS). The invention involves a therapeutic combination of drugs, including RNA silencing agents and targeting agents, which can selectively inhibit the expression of the Apolipoprotein E (ApoE) gene in the CNS while minimizing off-target effects. The patent provides detailed information on the composition and administration of these drugs for the treatment of neurodegenerative diseases. [Extracted from the article]

A patent application titled "Direct Raav-Mediated In Vivo Gene Editing Of Hematopoietic Stem Cells" has been published online by the US Patent and Trademark Office. The patent application, filed by inventors Terence Flotte and Allison Keeler-Klunk, is assigned to the University of Massachusetts. The application describes compositions and methods for gene editing in cells or subjects, specifically targeting hematopoietic stem cells for the treatment of hemoglobinopathies such as sickle cell disease. The disclosure includes details about the nucleic acids, adeno-associated viruses (AAVs), and gene products involved in the gene editing process. The patent application also mentions the use of guide RNAs (gRNAs) and RNA-guided nucleases (RGNs) in the method. [Extracted from the article]

A patent has been issued to the University of Massachusetts for therapeutic targets for facioscapulohumeral muscular dystrophy (FSHD). FSHD is caused by the aberrant expression of the DUX4 gene, which leads to muscle pathology and weakness. Current treatments for FSHD only address behavioral symptoms, so there is a need for novel therapies. The patent describes compositions and methods for treating FSHD by epigenetically regulating the expression of DUX4, which could reduce disease symptoms. The patent also mentions specific inhibitors that could be used to target DUX4 gene expression. [Extracted from the article]

A patent has been issued to the University of Massachusetts for compositions and methods for transient delivery of nucleases. Gene editing using designer DNA sequence-specific nucleases has emerged as a technology for both basic biomedical research and therapeutic development. However, safety concerns arise due to off-target effects and genotoxicity. This patent describes a method using viruses, specifically adeno-associated viruses (AAVs), to transiently deliver nucleases to cells, reducing off-target effects and genotoxicity. The method involves administering a recombinant AAV with a capsid protein that has a terminally grafted Cas-family nuclease. This technology has the potential to enable more precise and safe gene editing for therapeutic purposes. [Extracted from the article]

The University of Massachusetts has filed a patent application for a method of treating amyotrophic lateral sclerosis (ALS) by inhibiting the expression of SOD1 proteins using recombinant adeno-associated viruses (rAAVs). The application, titled "Sod1 Dual Expression Vectors And Uses Thereof," describes synthetic nucleic acids and constructs that can silence endogenous SOD1 while expressing exogenous SOD1 that is resistant to inhibition. The method involves delivering these nucleic acids to cells in the central nervous system to target neurons and reduce the expression of mutant SOD1 proteins associated with ALS. The patent application provides detailed information on the composition, delivery methods, and potential therapeutic applications of these rAAVs. [Extracted from the article]

A patent has been issued for anti-angiogenic miRNA therapeutics for inhibiting corneal neovascularization. Corneal neovascularization is a common pathological process in corneal diseases that can lead to blindness. The patent describes the use of recombinant adeno-associated virus (rAAV) vectors with specific capsid proteins to deliver transgenes to ocular tissue, specifically corneal tissue, more efficiently. This method could be used to treat or prevent eye diseases, including corneal neovascularization. The patent is assigned to the University of Massachusetts. [Extracted from the article]

A patent application has been filed by inventors from the University of Massachusetts for a self-regulating adeno-associated virus (AAV) vector that could potentially treat Rett syndrome, a neurological disease caused by mutations in the MECP2 gene. The inventors have discovered that certain combinations of miRNA regulatory elements can control the expression of a transgene within a specific range, which could help prevent off-target transgene toxicity. The patent application describes methods of engineering a transgene and recombinant nucleic acids with miRNA binding sites, as well as viral vectors and compositions for the treatment of Rett syndrome. The application provides detailed descriptions of these methods and their potential applications in gene therapy. [Extracted from the article]

A patent has been issued to the University of Massachusetts for compositions and methods to modulate dysferlin expression. Dysferlin is a protein involved in membrane repair, and insufficient levels of dysferlin can lead to specific forms of muscular dystrophy. The patent describes a new deep intronic mutation that alters the splicing of dysferlin mRNA, resulting in the inclusion of a pseudoexon. The invention provides a strategy to restore normal mRNA splicing and protein levels using antisense nucleic acids. This research offers potential therapeutic approaches for treating dysferlinopathies, which currently have no cure. [Extracted from the article]

A patent application from the University of Massachusetts has been made available online, detailing new adeno-associated viruses (AAVs) for gene therapy. These AAVs have variations in their capsid proteins that allow them to target specific tissues, including the liver, central nervous system, ocular tissue, gastrointestinal tract, respiratory system, breast tissue, pancreatic tissue, urinary tract tissue, uterine tissue, and tissue associated with certain cancers. The application also discusses methods for delivering transgenes to subjects and creating somatic transgenic animal models using these AAVs. The inventors of this patent application are Guangping Gao, Li Luo, Phillip Tai, Yuquan Wei, and Guangchao Xu from the University of Massachusetts. [Extracted from the article]

The University of Massachusetts has been issued a patent for a method of immunizing individuals against respiratory syncytial virus (RSV). RSV is a common cause of respiratory disease in infants, children, the elderly, and immunocompromised individuals. The patent addresses challenges in RSV vaccine development, such as safety and the generation of high levels of neutralizing antibodies. The method involves using a recombinant chimeric Newcastle Disease virus-like particle (ND VLP) to stimulate the production of RSV neutralizing antibodies in individuals who have previously been exposed to RSV. For more information, please refer to the full patent. [Extracted from the article]

A patent has been issued to the University of Massachusetts for methods of treating wounds using epigenetic regulation. The patent describes the use of DNA methyltransferase 1 (DNMT1) inhibitors and nicotinamide adenine dinucleotide phosphate oxidase 2 (NOX2) inhibitors to accelerate wound healing. The inventors propose that these inhibitors can upregulate certain genes involved in wound healing and reduce the number of inflammatory cells, leading to improved healing. This research is particularly relevant for individuals with type 2 diabetes mellitus, who have a higher risk of impaired wound healing and limb loss. [Extracted from the article]

A patent has been issued for bivalent dengue/hepatitis B vaccines by the University of Massachusetts. The invention aims to develop a vaccine that can provide simultaneous protection against infection with two or more different viruses. The vaccine contains antigenic epitopes against the dengue viruses and at least one antigenic epitope against the hepatitis B virus. The invention also includes methods for immunizing mammals with the bivalent vaccine peptide to produce protective levels of neutralizing antibodies. [Extracted from the article]

The rAAV of claim 16, wherein the RNA transcript encodes a therapeutic protein, optionally wherein the RNA transcript is an inhibitory RNA. A recombinant Adeno-Associated Virus (rAAV) comprising a transgene encoding an RNA transcript that comprises at least one immune-associated miRNA binding sites, wherein the at least one immune-associated miRNA binding site is a miR-652-5pBS, alone or in combination with one or more of the following miRNA binding sites: a miR-33-5pBS, a miR-223BS, or a miR142BS. The rAAV of claim 16, wherein the RNA transcript is a messenger RNA (mRNA) and at least one of the miRNA binding sites is present in the 3'-UTR of the messenger RNA, optionally wherein the RNA transcript is a mRNA and each of the miRNA binding sites is present in the 3'-UTR of the messenger RNA. [Extracted from the article]

The rAAV of claim 12, wherein the capsid protein is AAV9 capsid protein or AAVrh.10 capsid protein. Keywords: Bioengineering; Biotechnology; Capsid; Dismutase; Drugs and Therapies; Engineering; Enzymes and Coenzymes; Gene Therapy; Genetics; Nucleocapsid; Nucleocapsid Proteins; Risk and Prevention; University of Massachusetts; Viral Proteins; Viral RNA; Virions; miRNA-Based Therapy EN Bioengineering Biotechnology Capsid Dismutase Drugs and Therapies Engineering Enzymes and Coenzymes Gene Therapy Genetics Nucleocapsid Nucleocapsid Proteins Risk and Prevention University of Massachusetts Viral Proteins Viral RNA Virions miRNA-Based Therapy 3619 3619 1 09/19/23 20230918 NES 230918 2023 SEP 22 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent by the inventors Brown, Robert H. (Needham, MA, US), Mueller, Christian (Concord, MA, US), filed on September 21, 2018, was published online on August 29, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. The isolated nucleic acid of claim 1, wherein the exogenous mRNA encoding the SOD1 protein has one or more silent base pair mutations relative to the endogenous mRNA. [Extracted from the article]

Keywords: Angiogenesis; Antisense Technology; Bioengineering; Biotechnology; Drugs and Therapies; Genetics; Health and Medicine; Obstetrics; Preeclampsia; Pregnancy Complications; Therapeutics; Therapy; University of Massachusetts; Women's Health; siRNA-Based Therapy EN Angiogenesis Antisense Technology Bioengineering Biotechnology Drugs and Therapies Genetics Health and Medicine Obstetrics Preeclampsia Pregnancy Complications Therapeutics Therapy University of Massachusetts Women's Health siRNA-Based Therapy 3365 3365 1 08/07/23 20230808 NES 230808 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent by the inventors Biscans, Annabelle (Cambridge, MA, US), Davis, Sarah (Wellesley, MA, US), Hariharan, Vignesh Narayan (Natick, MA, US), Karumanchi, Ananth (Chestnut Hill, MA, US), Khvorova, Anastasia (Westborough, MA, US), filed on June 22, 2022, was published online on July 18, 2023, according to news reporting originating from Alexandria, Virginia, by NewsRx correspondents. Optimized anti-FLT1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders. [Extracted from the article]

A recombinant adeno-associated virus (rAAV) comprising at least one AAV capsid protein and the recombinant nucleic acid of claim 1. In some embodiments, compositions and methods described by the disclosure are therefore useful for treating diseases and disorders associated with loss of function mutations, for example Rett syndrome which is associated with loss of function mutations in the MECP2 gene. Keywords: Adeno-Associated Virus; Bioengineering; Biotechnology; Capsid; Central Nervous System Diseases and Conditions; Drugs and Therapies; Engineering; Gene Therapy; Genetics; Health and Medicine; Nervous System Diseases and Conditions; Nervous System Heredodegenerative Disorders; Neurobehavioral Manifestations; Neurodegenerative Diseases and Conditions; Neurologic Manifestations; Nucleocapsid; Nucleocapsid Proteins; Rett Syndrome; University of Massachusetts; Viral Proteins; Virions; Virology; X-Linked Mental Retardation EN Adeno-Associated Virus Bioengineering Biotechnology Capsid Central Nervous System Diseases and Conditions Drugs and Therapies Engineering Gene Therapy Genetics Health and Medicine Nervous System Diseases and Conditions Nervous System Heredodegenerative Disorders Neurobehavioral Manifestations Neurodegenerative Diseases and Conditions Neurologic Manifestations Nucleocapsid Nucleocapsid Proteins Rett Syndrome University of Massachusetts Viral Proteins Virions Virology X-Linked Mental Retardation 3641 3641 1 07/10/23 20230714 NES 230714 2023 JUL 14 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- University of Massachusetts (Boston, Massachusetts, United States) has been issued patent number 11680275, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. [Extracted from the article]

A composition comprising: (i) a first recombinant adeno-associated virus (rAAV) particle comprising the isolated nucleic acid of any one of claims 1 to 14; and (ii) a second rAAV particle encoding an RNA-guided nuclease, optionally, wherein the RNA-guided nuclease is a Cas13 nuclease. The method of any one of claims 39-44, wherein the RNA-guided nuclease is a Cas13 nuclease, optionally wherein the Cas13 nuclease is Cas13b, Cas13d, or dCas13d. The isolated nucleic acid of any one of claims 1 to 14, wherein the expression construct further comprises: (v) a sequence encoding an RNA-guided nuclease; optionally, wherein the RNA-guided nuclease is a Cas13 nuclease. The composition of claim 21, wherein the composition further comprises an isolated nucleic acid encoding an RNA-guided nuclease, optionally wherein the RNA-guided nuclease is a Cas13 nuclease. [Extracted from the article]

"In some embodiments, the isolated nucleic acid further comprises a IRES or a 2A peptide coding sequence, wherein the IRES or 2A is located between the FKBP12-zinc finger protein fusion protein and the FRB-p65 fusion protein. In some embodiments, the FKBP12-zinc finger protein fusion protein comprises an amino acid sequence at least 80% identical to amino acid sequence of SEQ ID NO: 1. "In some aspects, the present disclosure provides a recombinant adeno-associated virus (rAAV), comprising: (i) an AAV capsid protein; and (ii) an isolated nucleic acid comprising, in 5' to 3' order: (a) a 5' AAV ITR; (b) a regulatable promoter; (c) a first transgene; (d) a second promoter; (e) a second transgene comprising a nucleotide sequence encoding a FRB-p65 fusion protein, a nucleotide sequence encoding an internal ribosome entry site (IRES), a nucleotide sequence encoding a FKBP-zinc finder binding domain fusion protein; and (f) a 3' AAV ITR. Keywords: Adeno-Associated Virus; Amino Acids; Antibiotics; Artificial miRNA; Bioengineering; Biotechnology; Drugs and Therapies; Fusion Proteins; Gene Therapy; Genetics; Peptides; Pharmaceuticals; Proteins; Rapamycin Therapy; University of Massachusetts; Viral RNA; Virology; miRNA-Based Therapy EN Adeno-Associated Virus Amino Acids Antibiotics Artificial miRNA Bioengineering Biotechnology Drugs and Therapies Fusion Proteins Gene Therapy Genetics Peptides Pharmaceuticals Proteins Rapamycin Therapy University of Massachusetts Viral RNA Virology miRNA-Based Therapy 612 612 1 04/10/23 20230413 NES 230413 2023 APR 13 (NewsRx) -- By a News Reporter-Staff News Editor at Gene Therapy Weekly -- A patent application by the inventors Aronin, Neil (Newtonville, MA, US); Mueller, Christian (Concord, MA, US), filed on February 24, 2021, was made available online on March 23, 2023, according to news reporting originating from Washington, D.C., by NewsRx correspondents. [Extracted from the article]

"In further embodiments, the elevator device includes markings on the elevator element to indicate the depth of insertion of the elevator element into a subject. A groove for receiving a bone structure, the groove being located on a first (upper) surface of the distal portion of the elevator element portion; and a base on a second surface of the elevator device. "According to one embodiment of the present invention, a surgical elevator device comprises a elevator element that is inserted under the bone, the elevator element having a distal end and a proximal end, an upper surface. [Extracted from the article]

According to the news editors, the research concluded: "Thus, allele-specific targeting of InDel and insertion mutations to heterozygous coding region SNPs provides a feasible approach to inactivate autosomal dominant mutations that cause genetic disease." Inactivation of the mutant allele by clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 based gene editing offers a possible therapeutic approach for this disease, but permanent disruption of normal HTT function might compromise adult neuronal function." Keywords: Worcester; Massachusetts; United States; North and Central America; Bioengineering; Biotechnology; CRISPR; Drugs and Therapies; Gene Editing; Gene Therapy; Genetics; Genome Editing; University of Massachusetts; State:Massachusetts EN Worcester Massachusetts United States North and Central America Bioengineering Biotechnology CRISPR Drugs and Therapies Gene Editing Gene Therapy Genetics Genome Editing University of Massachusetts State:Massachusetts Researchers detail new data in Biotechnology - Gene Therapy. [Extracted from the article]

Highlight research on diabetes pathogenesis. Analysis of insulin signaling by RNAi-based gene silencing; Protective effect of phosphatidylinositol 4,5-bisphosphate against cortical filamentous actin loss and insulin resistance induced by sustained exposure of 3T3-L1 adipocytes to insulin; Presence of enhanced insulin-mediated glucose uptake in skeletal muscle in syntaxin 4 transgenic mice.

Details some research from the United States, which outlined data on diabetes pathogenesis. Authors of the studies; Implications of the findings for diabetes pathogenesis research; Periodical where the studies were published.

Details some research from the United States, Turkey and Slovakia that are focus on obesity and diabetes. Authors of the studies; Implications of the findings for diabetes research; Periodical where the study was published.

Discusses findings of the study "The sequelae of untreated maternal hypothyroidism," by M.L. Mitchell and R.Z.. Klein of the University of Massachusetts, and published in the "European Journal of Endocrinology" . Study design and methods; Objectives and findings of the study.

Reports on the discovery of a novel therapeutic targets in the battle of the bulge. Analysis of the effects of C/EBP gene replacement in mice; Role of C/EBP protein in promoting adipogenesis; Effectiveness of C/EBP gene replacement in preventing obesity.

Independent research groups have discovered novel therapeutic targets in the battle of the bulge. By altering the expression of a single - albeit different--gene, researchers Roger Davis and Ying-Hue Lee have succeeded in creating two different strains of transgenic mice that don't gain weight, even when fed fat-laden, high-calorie diets. Their reports were published in the August 15, 2004, edition of "Genes & Development." Lee and colleagues utilized an existing strain of mice that contains the alpha-to-beta gene substitution, referred to in the paper as "beta/beta mice." They found that beta/beta mice not only live an average of 5 months longer than wild-type mice, but are markedly leaner, apparently burning fat at a much higher rate than normal mice.

Reports on the researcher's study of historical disease trends in an era when modern medicine and sanitation were emerging. Emphasis on the importance of knowing the public health in the past; Evolution of public health and sanitation as germ theory; Focus of the study on two Massachusetts industrial cities.

Chris Kilham, 51, is a medicine hunter, a sort of Indiana Jones of the plant world. Hired by companies that market herbal remedies for ailments ranging from the common cold to depression, Kilham has spent the past decade roaming remote areas of the globe in search of the next best botanical. But he's also a businessman who talks about a social and environmental ethic. Along with promoting medicinal plants, Kilham said he's on a mission to preserve and protect natural environments while helping the indigenous people who live there.

This article presents findings of a study previously published in the medical journal "Springer Seminars in Immunopathology," conducted by researcher Kenneth L. Rock. The study reviews natural endogenous adjuvants. It has long been known that immunization with a protein by itself is often not sufficient to stimulate immunity, and may instead induce tolerance. To elicit productive immune responses exogenous adjuvants need to be co-injected with an antigen. One important class of adjuvants are the unique components of microbes. It is now believed that an adjuvant is required for immunity because the immune system evolved to respond to dangerous situations such as infections, and the presence of an adjuvant is the mechanism used to identify these situations.

This article focuses on a study which shows that incarcerated women need focused services that address the differences that exist inside and outside of prison walls for women inmates in order to allow them to remain connected to their children and families. Female inmates are almost three times more likely than incarcerated men to have been the primary caregiver for children prior to their incarceration, according to researchers at the Center for Women in Politics and Public Policy at the McCormack Graduate School of Policy Studies, who examined state and county correctional facilities in Massachusetts.

The article cites a study on natural endogenous adjuvants. Researcher Kenneth L. Rock and colleagues at the University of Massachusetts indicated that, to elicit productive immune responses exogenous adjuvants need to be co-injected with an antigen. One important class of adjuvants are the unique components of microbes. It is now believed that an adjuvant is required for immunity because the immune system evolved to respond to dangerous situations such as infections, and the presence of an adjuvant is the mechanism used to identify these situations. Rock and his collaborators published their study in the journal "Springer Seminars in Immunopathology."

Discusses the findings of a study which identified drug events in nursing homes far more common that previously identified . Tests conducted; Implications for medical science and biotechnology research.

Presents the results of a study on the occurrence of injuries from adverse drug events in the long-term care setting. Ways to prevent drug-related injuries in the long-term care facilities; Classifications of the drug events that caused injury to the patient; Factors that caused the drug events.

The article informs that an environmental contaminant, bisphenol-A, has been shown to increase serum thyroxine concentrations and alter expression of a thyroid hormone-responsive gene in the developing rat brain. Considering the importance of thyroid hormone (TH) in brain development, it is of potential concern that a wide variety of environmental chemicals can interfere with thyroid function or, perhaps of greater concern, with TH action at its receptor (TR), reported R.T. Zoeller and colleagues, University of Massachusetts. Zoeller and coauthors published their study in the periodcial "Endocrinology."

Discusses research studies from the United States, Turkey and Slovakia concerning obesity and diabetes. Implication of the research on the field of biotechnology; Basis for the conclusion; Authors of the study; Periodical that published the research.

Discusses findings of the study "The histone fold domain of Cse4 is sufficient for CEN targeting and propagation of active centromeres in budding yeast," by L. Morey and colleagues, University of Massachusetts, and published in the "Eukaryotic Cell". Study design and methods; Objectives and findings of the study.

This article presents findings of a research previously published in the medical journal "Eukaryotic Cell," conducted by researcher L. Morey. According to a study from the United States, the histone fold domain of Cse4 is sufficient for targeting and propagation of active centromeres in budding yeast. Centromere-specific H3-like proteins (CenH3s) are conserved across the eukaryotic kingdom and are required for packaging centromere DNA into a specialized chromatin structure required for kinetochore assembly. Cse4 is the CenH3 protein of the budding yeast Saccharomyces cerevisiae.

Discusses a research study which shows that acute myocardial infarction patients changed in profile over the last 25 years. Implication of the research on the field of biotechnology; Basis for the conclusion; Authors of the study; Periodical that published the research.